MedTrace Logo

Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK

NCT04532645 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 342

Last updated 2025-09-23

No results posted yet for this study

Summary

This is a retrospective observational medical records review study of BRCA mutated advanced (FIGO stage III-IV) ovarian cancer patients who received first dose maintenance olaparib in 1L setting in France, Italy and the UK. Physicians who treated ovarian cancer patients with olaparib in 1L setting will be requested to recruit patients to have their clinical data abstracted from their clinical records in line with local laws

Conditions

  • Ovary Cancer

Interventions

DRUG

Olaparib

Olaparib

Sponsors & Collaborators

Principal Investigators

  • Charlie Gourley, MD, PhD · University of Edinburgh

  • Domenica Lorusso, MD · Fondazione Policlinico Universitario Agostino Gemelli IRCCS

  • Delphine Garbay, MD · Institut Bergonie, France

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-07
Primary Completion
2024-09-27
Completion
2024-09-27
FDA Drug
Yes

Countries

  • France
  • Italy
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04532645 on ClinicalTrials.gov